Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Watson

- PMLiVE

Pfizer and Flagship Pioneering enter autoimmune disease partnership

More than 100 known types of autoimmune diseases affect over 50 million people in the US

- PMLiVE

Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

- PMLiVE

Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study

It is estimated that nearly 320,000 people will be diagnosed with the disease in the US this year

- PMLiVE

Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

- PMLiVE

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

An estimated 154,270 people will be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

Pfizer shares positive late-stage results for Braftovi regimen in colorectal cancer

The combination was approved in the US last month to treat BRAF V600E-mutant disease

- PMLiVE

Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager

The candidate targets a tumour antigen that is highly expressed across several cancer types

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

- PMLiVE

Pfizer appoints Chris Boshoff as chief scientific officer and president of R&D

Boshoff has most recently been serving as the company’s chief oncology officer and executive vice president

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links